Jan 14 2021 Read 266 Times
University of Birmingham (UK) scientists have shown that a novel low molecular weight dextran-sulphate, ILB® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease, affecting over 70 million people worldwide, by lowering increased intraocular pressure (IOP) within the eye’s main fluid drainage site.,
OAG develops slowly over many years, leading to excessive matrix deposition (fibrosis), which in turn can lead to increased intraocular pressure (IOP), causing damage to the optic nerve and blindness.
The research has shown that that ILB can normalise matrix deposition inside the eye in a pre-clinical model used to mimic these aspects of human glaucoma, paving the way for new anti-fibrotic therapies to be developed for the disease.
Novel low molecular weight dextran-sulphate could play a key role in glaucoma treatment
Scientists at the University of Birmingham, UK, have shown that a novel low molecular weight dextran-sulphate, ILB
® could play a key role in treating open angle glaucoma (OAG), a neurodegenerative disease that affects over 70 million people worldwide and causes irreversible blindness.
OAG develops slowly over many years. Excessive matrix deposition (fibrosis) within the eye s main fluid drainage site can lead to increased intraocular pressure (IOP), resulting in damage to the optic nerve.
The research, reported in npj Regenerative Medicine, has shown that that ILB can normalize matrix deposition inside the eye and lower IOP in a pre-clinical model used to mimic these aspects of human glaucoma, paving the way for new anti-fibrotic therapies to be developed for the disease.